LYT-200 + Chemotherapy/Tislelizumab for Cancer
Trial Summary
What is the purpose of this trial?
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
Research Team
Aleksandra Filipovic, MD, Ph.D.
Principal Investigator
PureTech Health
Eligibility Criteria
Adults with certain advanced cancers (like head and neck, pancreatic, bladder, or colorectal) that can't be removed by surgery. They should have measurable disease and be able to undergo biopsies. Prior immunotherapy is okay if they meet response criteria. Must not be pregnant and agree to contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation Phase - Single Agent
A dose-finding study using a continuous reassessment method to establish dose-limiting toxicities and the recommended Phase 2 dose
Dose Escalation Phase - Combination
A dose-finding combination study with chemotherapy or tislelizumab using a 4+2 study design to establish dose-limiting toxicities and the recommended Phase 2 dose
Dose Expansion Phase
Dose expansion in single agent or combination based on the recommended Phase 2 dose determined in Part 1
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Anti-PD-1
- Gemcitabine/nab-paclitaxel
- LYT-200
- Tislelizumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
PureTech
Lead Sponsor